Investigating the effect of VEGF glycosylation on glycosaminoglycan binding and protein unfolding

被引：30
作者：
Brandner, B
Kurkela, R
Vihko, P
Kungl, AJ [1 ]
机构：
[1] Graz Univ, Inst Pharmaceut Sci, A-8010 Graz, Austria
[2] Oulu Univ, Bioctr Oulu, FIN-90014 Oulu, Finland
来源：
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 2006年 / 340卷 / 03期
关键词：
growth factor; heparin; heparan sulfate;
D O I：
10.1016/j.bbrc.2005.12.079
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
VEGF(165) binding to endothelial cells is potentiated by glycosaminoglycans (GAGs). Here, we have investigated the impact of VEGF(165) N-glycosylation on GAG binding. Although glycosylated VEGF(165) bound to heparin with only slightly higher affinity than non-glycosylated VEGF(165), the natural ligand heparan sulfate induced a conformational change only in the glycosylated protein. Unfolding studies of the VEGF proteins indicated a stabilising effect of heparin on the growth factor structure. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码：836 / 839
页数：4
相关论文
共 29 条
  • [11] Vascular endothelial growth factor 165 (VEGF165) activities are inhibited by carboxymethyl benzylamide dextran that competes for heparin binding to VEGF165 and VEGF165•KDR complexes
    Hamma-Kourbali, Y
    Vassy, R
    Starzec, A
    Le Meuth-Metzinger, V
    Oudar, O
    Bagheri-Yarmand, R
    Perret, G
    Crépin, M
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (43) : 39748 - 39754
  • [12] THE VASCULAR ENDOTHELIAL GROWTH-FACTOR FAMILY - IDENTIFICATION OF A 4TH MOLECULAR-SPECIES AND CHARACTERIZATION OF ALTERNATIVE SPLICING OF RNA
    HOUCK, KA
    FERRARA, N
    WINER, J
    CACHIANES, G
    LI, B
    LEUNG, DW
    [J]. MOLECULAR ENDOCRINOLOGY, 1991, 5 (12) : 1806 - 1814
  • [13] HOUCK KA, 1992, J BIOL CHEM, V267, P26031
  • [14] Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro
    Jayson, GC
    Lyon, M
    Paraskeva, C
    Turnbull, JE
    Deakin, JA
    Gallagher, JT
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (01) : 51 - 57
  • [15] Disulfide structure of the heparin binding domain in vascular endothelial growth factor: Characterization of posttranslational modifications in VEGF
    Keck, RG
    Berleau, L
    Harris, R
    Keyt, BA
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1997, 344 (01) : 103 - 113
  • [16] The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency
    Keyt, BA
    Berleau, LT
    Nguyen, HV
    Chen, H
    Heinsohn, H
    Vandlen, R
    Ferrara, N
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (13) : 7788 - 7795
  • [17] Regulated diversity of heparan sulfate
    Lindahl, U
    Kusche-Gullberg, M
    Kjellén, L
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (39) : 24979 - 24982
  • [18] Structural features in heparin that interact with VEGF165 and modulate its biological activity
    Ono, K
    Hattori, H
    Takeshita, S
    Kurita, A
    Ishihara, M
    [J]. GLYCOBIOLOGY, 1999, 9 (07) : 705 - 711
  • [19] GLYCOSYLATION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR IS NOT REQUIRED FOR ITS MITOGENIC ACTIVITY
    PERETZ, D
    GITAYGOREN, H
    SAFRAN, M
    KIMMEL, N
    GOSPODAROWICZ, D
    NEUFELD, G
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 182 (03) : 1340 - 1347
  • [20] Heparin and heparan sulfate: structure and function
    Rabenstein, DL
    [J]. NATURAL PRODUCT REPORTS, 2002, 19 (03) : 312 - 331
123